KemPharm Inc. (NASDAQ:KMPH) shares saw an uptick in trading volume on Friday . 123,918 shares traded hands during trading, an increase of 91% from the previous session’s volume of 65,007 shares.The stock last traded at $4.18 and had previously closed at $4.03.

Several research firms recently weighed in on KMPH. Oppenheimer Holdings Inc. reissued a “buy” rating and set a $11.00 price target on shares of KemPharm in a report on Tuesday, June 14th. Canaccord Genuity reissued a “buy” rating on shares of KemPharm in a report on Saturday, May 14th. Royal Bank Of Canada reissued a “buy” rating on shares of KemPharm in a report on Sunday, May 8th. Finally, Zacks Investment Research cut KemPharm from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $26.80.

The company’s market cap is $61.79 million. The company has a 50-day moving average price of $4.32 and a 200-day moving average price of $11.27.

KemPharm (NASDAQ:KMPH) last issued its quarterly earnings data on Thursday, May 12th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.26. Equities research analysts forecast that KemPharm Inc. will post ($2.79) earnings per share for the current year.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.